ARENSIA Exploratory Medicine GmbH’s Post

🌟 Exciting News! 🌟 We are thrilled to share that our CEO & Co-Founder, LakshmiDevi Ethirajan, will be moderating a panel at the 20th BioPharma Nexus Conference in San Diego. The panel discussion will focus on "Advancing Hit Discovery for Complex and Emerging Targets. Join us in San Diego on May 8-9 to gain insights from industry leaders and see how innovations are shaping the future of #DrugDiscovery!

A few weeks have gone by since our first one-day symposium, ‘Unlocking Early Drug Development’ took place at the Parc Científic de Barcelona, but we’re still buzzing with excitement from the incredible turnout! To everyone who participated, attendees, both in-person and online, speakers and sponsors, thank you for making this event so meaningful. It was inspiring to see so many bright minds come together to share their expertise and explore new possibilities in early drug development. We’ve put together a short video capturing the highlights of the day, which we'll be sharing shortly. If you missed the symposium or want to relive the key moments, stay tuned! And finally, for those companies interested in collaborating on a similar event next year, we’d love to hear your ideas. Whether you’re looking to sponsor, present, or co-organize, let’s explore how we can create another impactful event together. If you have any solid form challenges, remember that our team is ready to help you. Whether it's solid form characterization and screening, crystallization, particle size reduction, or early preclinical formulation development, we’re here to provide tailored solutions to your solid state needs. Thank you all once again for being part of this journey. Here's to pushing the boundaries of early drug development! #symposium #drugdevelopment #innovation #crystallization #partnership

What an incredible and thematic week it’s been! 🎉 I had the honor of moderating a panel at the Georgia Bio Life Sciences Summit on the critical steps of moving a therapeutic from the lab to active IND status. Our panel discussion on "Lab to Active IND - Understanding the Team That Will Get You There" was filled with valuable insights from industry experts: Anthony Chilton, COO at Radyus Research, Karin McIntosh, MPharm, RAC, VP of Regulatory Affairs at Atomwise, and David Penake, CEO of Saol Therapeutics. Together, we unpacked the intricacies of navigating the path from in vivo testing to IND submission—sharing experiences on what it takes to build a winning strategy. Key takeaways included: 🔑 The importance of a Target Product Profile to define your vision and guide development   🔑 The need for a well-structured product development plan to compress timelines and avoid common pitfalls  Yesterday’s webinar with Dr. Eric Springman, Head of Development at Radyus Research, connected perfectly with these ideas, serving as a strong reminder that every step matters in this process. He emphasized the importance of how risk assessment and gap analysis can identify potential roadblocks and ensure readiness for FDA approval. His insights on preclinical development reinforced the critical need for strategic planning to ensure that you stay on track, de-risk your program, and attract the right investors. It was a reminder that every step matters—whether it's accelerating timelines, managing regulatory complexities, or keeping investors engaged. At Radyus Research, we've built a team with extensive experience in this journey. From preclinical development through to IND submission, our focus is always on minimizing risks while maximizing speed and efficiency. As we discussed in both the panel and webinar, these are exactly the elements that make a difference when it comes to attracting and securing investors. Huge thank you to everyone who attended and engaged in the discussion, and to our expert panelists for their incredible insights! #DrugDevelopment #INDSubmission #Biotech #PreclinicalDevelopment #InvestInInnovation #LifeSciences #Pharma #ClinicalTrials #BiotechInvestors #RadyusResearch

This isn't your typical drug sponsor + CDMO story. CTMC's Jason Bock says you shouldn't even classify his company as a CDMO. He's not wrong. On #BusinessOfBiotech, Thomas Leitch of KSQ Therapeutics, Inc. and Jason share their partnership story. "Our platform led us to some unique and very promising targets. But as as you alluded to earlier, Matt, having a target is not the same thing as having a therapy. And having a therapy is not the same thing as delivering a patient outcome. And our partnership with CTMC has really helped us accelerate those leads for targeted therapy to uninterrupted supply and and ultimately patient outcomes." Tom Leitch, CTO at KSQ Therapeutics. "And so, because we were running these studies already with MD Anderson - we've done many of these studies - we've got all of those logistics worked out. And so for our partners, they don't have to bother with any of it, we coordinate directly within the MD Anderson clinic. When they have a patient, we work out that we make sure we have a slot and we manufacture that product and then keep them informed and get that product back to the clinicians to infuse into the patients. And so, partners have full visibility into what's going on." Jason Bock, CEO, CTMC+. Thank you, Matthew Pillar and Bioprocess Online, for sitting down with Jason and Tom to hear the story of this exciting partnership. #biotech #celltherapy #TILtherapy #endcancer

The wait is over, SCOPE 2024 is finally here! Segmed is thrilled to be attending the SCOPE Europe Summit tomorrow in Barcelona. We are excited to explore the latest trends in clinical trial innovation, planning, and operations at SCOPE Europe 2024. The conference offers a fantastic opportunity to learn from new case studies and network with industry leaders from pharma, Biotech, and clinical research organizations. Our curated, fit-for-purpose regulatory grade datasets and multimodal longitudinal datasets can transform and help optimize clinical trials. Let’s connect to discuss how real-world imaging datasets (RWiD) can enhance clinical trials through improved patient selection and data-driven insights. Our Chief Strategy Officer, Kristin Yakimow will be there at the #SCOPE summit. Join us to learn more about Segmed and how we can collaborate- https://hubs.li/Q02VxrFf0 Looking forward to productive conversations! #SCOPE2024 #ClinicalTrials #RWiD #Innovation #Pharma #Biotech #CRO #DrugDevelopment #Segmed #RWD #imagingdata #realworldimagingdata

🤝 In the world of 2024 pharma partnerships, no where is putting on a spectacle like ADCs and radioligands, Novartis' recent acquisition of Mariana Oncology the latest in a series of $billion deals in the last 12 months. ☀ But with the pressure to "make hay while the sun shines" how do ADC and RLT companies differentiate, validate or collaborate amidst a whirlwind of interest and activity? 🌟 ...enter the ADC & Radiopharmaceutical Pharma & Biotech Partnering Summit in Boston. The hyper-relevant partnership event delivering better access to disruptive science, capital and deals, for ADCs and RLTs. https://ter.li/ipq457 👥 Uniting S&E and BD&L from pharma with C-level and BD execs from Biotech, join the hottest and most targeted partnering initiative to gain visibility and traction across business-to-business buy/sell ADC opportunities, and align to translate the next generation of safe, effective and differentiated ADCs and RLTs through the clinic and to patients in need.

The premier biotechnology platform with professionals from the life sciences community ✅ ... for networking, engaging discussions, exploring progresses in research, manufacturing, marketing, data, financing ✅ ... you name it ✅ Swiss Biotech Association #swissbiotechday #swissbiotechday2024

#Article: It’s not all about patents and products. It’s people who drive innovation and inspiration in the pharma industry, helping bring ground breaking new medicines to patients in need.  The Medicine Maker invited its audience to throw the spotlight on their inspiring colleagues, peers, leaders, and mentors by submitting nominations for The Medicine Maker’s annual Power List. Here, 30 incredible players making waves in #smallmolecule, #biopharmaceutical, and #advancedmedicine drug development. In an age of political polarity, ongoing and emerging challenges to human health, conflict, and huge shifts in the ways we work, The Medicine Makers Power Listers continue to roll with the world’s punches, using their hard-won capital to generate positivity, inspiration, and innovation. Featuring #SmallMolecules Prof Marc Brown PhD CChem FRSC, Co-founder, MedPharm Matthew Clark, President and CSO, X-Chem J. Jean Cui, Scientific Founder, President, and CEO, BlossomHill Therapeutics Edward Hæggström, CEO, Nanoform Raquel Izumi, COO, President, and Founder, Vincerx Pharma Jerry McMahon, CEO, Storm Therapeutics Anders Nykjær Chief Scientific Officer, Vesper Bio Anne Phelan, CSO, BenevolentAI Mike Riley, CEO, Veranova Beatrice S.etnik, CSO, Altasciences #Biopharmaceuticals Alain Beck, Senior Director, Biologics CMC and Developability, Pierre Fabre Akintunde (Tunde) Bello, MSc, PhD, Snr VP, Head of Clinical Pharmacology, Pharmacometrics, and Bioanalysis, Bristol Myers Squibb Piers Ingram, CEO of Hummingbird Bioscience Mahesh Karande, President and CEO, Omega Therapeutics Seth Lederman, CEO, Tonix Pharmaceuticals Hanns-Christian Mahler, CEO, ten23 health Jane Osbourn OBE, CSO, Alchemab Therapeutics Mike Rea, CEO, IDEA Pharmaceuticals Aliasger Salem, Ass VP for Research, Bighley Chair and Professor of Pharmaceutical Sciences, University of Iowa Paul Peter Tak, MD PhD FMedSci, President and CEO, Candel Therapeutics #AdvancedMedicines Jeffrey Bluestone, CEO and Founder, Sonoma Bio Jason Bock, CEO, CTMC Teresa Foy, Snr VP, Cancer Immunology and Cell Therapy, Thematic Research Center, Bristol Myers Squibb Fabian Gerlinghaus, CEO and Co-Founder, Cellares Audrey Greenberg, CBO and Co-Founder, Center for Breakthrough Medicines, SK pharmteco Reshma Kewalramani, MD FASN, President and CEO, Vertex Pharmaceuticals Michael May, CEO and President, Centre for Commercialization of Regenerative Medicine Sheila Ann Mikhail, Co-founder, Asklepios BioPharmaceutical (AskBio) Phil Vanek, CTO and Partner, Gamma Biosciences Stella K. Vnook, CEO, Likarda Read about The Medicine Makers Power Listers 👇🏼 https://lnkd.in/eGa2xmAe